Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data
Abstract
192 children undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS,n=93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B,n=99). This manuscript reports the 2-year data on 85.4% (164) of the original patients.
There was a single death in the TAS arm. There was no significant difference in both treatment arms in 2 years graft survival as well as survival free from rejection, estimated glomerular filtration rate, blood pressure, cholesterol levels, in the incidence of infection or malignancy.
These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.